
Singapore · Research startup
Esco Lifesciences Group is a prominent life science company based in Singapore, specializing in the manufacturing of laboratory and biopharma equipment, IVF medical devices, and bioprocess tools.
Funding reportedLast round: Series A
Follow Esco and see its new rounds in your feed.Start following
Esco Lifesciences Group is a prominent life science company based in Singapore, specializing in the manufacturing of laboratory and biopharma equipment, IVF medical devices, and bioprocess tools.
Established in 1978, the company shifted its focus to life sciences in 2000 and now employs over 1,700 people across more than 54 locations, including six R&D units and six manufacturing sites. Esco's products are available in over 100 to 150 countries worldwide. The company offers a range of tailored, sustainable workflow solutions and high-value equipment for the life science and medical markets. Its core product portfolio includes biosafety cabinets, laboratory and biopharma equipment, IVF medical devices, and consumables. Esco serves a diverse clientele, including academic and research institutions, medical and clinical facilities, and the pharmaceutical and biotech industries. With a commitment to quality, Esco operates under ISO 9001 and ISO 14001 certified management systems, aiming to deliver technologies that promote a healthier and more equitable future.
Funding, as reported
What they build
Known for
biopharma equipmenthealth careanimal research workstationbioprocess validationenvironmentally friendly materialscell therapy equipmentcovid-19 testing equipmentvaccine manufacturing toolsrestricted access barrier systemmolecular diagnosticsivf solutionsbioprocessing toolsivf fertility solutionsbiotechnology researchdistributionmanufacturing
Built with from their website
Google MapsGoogle Tag ManagerTengineSalesforce CRM AnalyticsHREF LangAtlassianWOWGoogle AdsClarity SDMFont Awesome
YouTubeMicrosoft ProjectBaiduPapa ParseCloudFlareGemViewport MetaLinkedIn Ads
Add your raise, your deck and your story, and put Esco in front of investors. Or tell us what we have wrong.